Natalia Paulina Karczewska

Ms. Natalia Paulina Karczewska

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MWMałgorzata Wojtkowska
Małgorzata Wojtkowska
NKNatalia Paulina Karczewska
Natalia Paulina Karczewska
KPKlaudia Pacewicz
Klaudia Pacewicz
APAndrzej Pacak
Andrzej Pacak
PKPiotr Kopeć
Piotr Kopeć
BSBartosz Sokół
Bartosz Sokół
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders globally and leads to an excessive loss of dopaminergic neurons in the substantia nigra of the brain. Circulating cell-free DNA (ccf-DNA) are double-stranded DNA fragments of different sizes and origins that are released into the serum and cerebrospinal fluid (CSF) due to cell death (i.e., necrosis and apoptosis) or are actively released by viable cells via exocytosis and NETosis. Using droplet digital polymerase chain reaction (ddPCR), we comprehensively analyzed and distinguished circulating cell-free mitochondrial DNA (ccf mtDNA) and circulating cell-free nuclear DNA (ccfDNA) in the serum and CSF of PD and control patients. The quantitative analysis of serum ccf-DNA in PD patients demonstrated a significant increase in ccf mtDNA and ccfDNA compared to that in healthy control patients and a significantly higher copy of ccf mtDNA when compared to ccfDNA. Next, the serum ccf mtDNA levels significantly increased in male PD patients compared to those in healthy male controls. Furthermore, CSF ccf mtDNA in PD patients increased significantly compared to ccfDNA, and ccf mtDNA decreased in PD patients more than it did in healthy controls. These decreases were not statistically significant but were in agreement with previous data. Interestingly, ccf mtDNA increased in healthy control patients in both serum and CSF as compared to ccfDNA. The small sample size of serum and CSF were the main limitations of this study. To the best of our knowledge, this is the first comprehensive study on serum and CSF of PD patients using ddPCR to indicate the distribution of the copy number of ccf mtDNA as well as ccfDNA. If validated, we suggest that ccf mtDNA has greater potential than ccfDNA to lead the development of novel treatments for PD patients.

29 January 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MWMałgorzata Wojtkowska
Małgorzata Wojtkowska
NKNatalia Paulina Karczewska
Natalia Paulina Karczewska
KPKlaudia Pacewicz
Klaudia Pacewicz
APAndrzej Pacak
Andrzej Pacak
PKPiotr Kopeć
Piotr Kopeć
BSBartosz Sokół
Bartosz Sokół
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders globally, and leads to an excessive loss of dopaminergic neurons in the substantia nigra of the brain. Circulating cell-free DNA (ccf-DNA) are double-stranded DNA fragments of different sizes and origins that are released into the serum and cerebrospinal fluid (CSF) due to cell death (i.e., necrosis and apoptosis) or are actively released by viable cells via exocytosis and NETosis. Methods: Using droplet digital polymerase chain reaction (ddPCR) we comprehensively analyzed and distinguished ccfDNA and ccf mtDNA in the serum and CSF of PD and control patients. Results: The quantitative analysis of serum ccf-DNA in PD patients demonstrated significant increase of ccf mtDNA and ccfDNA compared to healthy control patients and significantly higher copy of ccf mtDNA when compared to ccfDNA. Next, the serum ccf mtDNA levels significantly increased in male PD patients compared to healthy male controls. Furthermore, CSF ccf mtDNA in PD patients increased significantly compared to ccfDNA, and ccf mtDNA decreased in PD patients compared to healthy controls. These decreases were not statistically significant, but were in agreement with previous data. In-terestingly, ccf mtDNA increased in healthy control patients in both serum and CSF as compared to ccfDNA. Limitations: the small sample size of serum and CSF were the main limitations of this study. Conclusion: To the best of our knowledge, this is the first comprehensive study on serum and CSF of PD patients using ddPCR and indicating the distribution of the copy number of ccf mtDNA, as well as ccfDNA. If validated, we suggest that ccf mtDNA has greater than ccfDNA potential to lead the development of novel treatments for PD patients.

1 July 2024 in Postępy Biochemii
Verified
Journal Article
Open access
PDF file
NKNatalia Paulina Karczewska
Natalia Paulina Karczewska
MPMonika Pyc
Monika Pyc
KŻKrzysztof Żukowski
Krzysztof Żukowski
JKJoanna Kosman
Joanna Kosman
DKDorota Kwiatek
Dorota Kwiatek
JKJacek Kolanowski
Jacek Kolanowski
With the development of medicine and the aging population, the demand for more effective therapies is escalating. A tool that facilitates the discovery and introduction of new therapeutic drugs is High-Throughput Screening (HTS). These tests, consisting of a wide set of various assays, allow testing hundreds of thousands of compounds in a short period of time. The aim is to accurately identify active compounds that could become potential therapeutic candidates in the pharmaceutical industry. HTS is the first step in the quest for potential drugs, therefore it is one of the crucial tests that determine whether a particular drug candidate will be discovered. In this review, different stages of high-throughput screening studies will be described, as well as methods utilized in these studies. The necessary steps in the optimization of these tests, selection of equipment, automation and key quality control parameters for reliably performed screening will also be presented.